» Articles » PMID: 32641139

Factors Associated with Refractory Autoimmune Necrotizing Myopathy with Anti-signal Recognition Particle Antibodies

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2020 Jul 10
PMID 32641139
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Autoimmune necrotizing myopathy with anti-signal recognition particle antibodies (ANM-SRP) is regarded as refractory myositis, whereby some patients respond poorly to conventional immunosuppression and require B cell depletion treatment. This study aimed to evaluate factors associated with refractory ANM-SRP.

Results: Clinical and pathological data from 48 patients with ANM-SRP were collected. We followed up clinical symptoms and image changes over 12 months. Univariate and multivariate analyses were undertaken to determine the associations between variables of interest and poor response to therapy. Refractory ANM-SRP appeared in 32.5% of patients who showed no or minimal improvement after 12 months of steroid therapy. The clinical risk factors for refractory patients were being male (OR, 19.57; P < 0.001), severe muscle weakness (OR, 7.51; P < 0.001) and concurrent interstitial lung disease (OR, 39.70; P < 0.001). The imaging refractory-related factor was the fatty infiltration rate of thigh muscles over 3 months (P = 0.022) and the pathological factor associated with refractory ANM-SRP was the high expression of B cell activating factor receptor (BAFF-R) in muscle (P = 0.036).

Conclusion: Being male, severe muscle weakness, concurrent interstitial lung disease, quick development of muscle fatty infiltration and more BAFF-R and B lymphocyte infiltration in muscle indicate a poor response to immunosuppressive therapy in patients with ANM-SRP.

Citing Articles

Identification of clinical subgroups in anti-SRP positive immune-mediated necrotizing myopathy patients using cluster analysis.

Cui B, Liu H, Liu R, Yin G, Xie Q Ther Adv Musculoskelet Dis. 2025; 17:1759720X251314697.

PMID: 39881842 PMC: 11775970. DOI: 10.1177/1759720X251314697.


CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM.

Sun H, Wang Z, Han Y, Wei X, Wang Y, Yu X Ann Clin Transl Neurol. 2024; 11(5):1267-1279.

PMID: 38651547 PMC: 11093240. DOI: 10.1002/acn3.52065.


Interpreting a Delayed Workup of Idiopathic Inflammatory Myopathy.

Terrani K, Ibrahim R, Ferris S, Brucks E Cureus. 2024; 16(3):e55580.

PMID: 38576668 PMC: 10994402. DOI: 10.7759/cureus.55580.


From data to diagnosis: how machine learning is revolutionizing biomarker discovery in idiopathic inflammatory myopathies.

McLeish E, Slater N, Mastaglia F, Needham M, Coudert J Brief Bioinform. 2024; 25(1).

PMID: 38243695 PMC: 10796252. DOI: 10.1093/bib/bbad514.


Anti-SRP-positive necrotising myopathy concurrent with breast malignancy.

Dandasena T, Ingle V, Singhai A, Saigal S BMJ Case Rep. 2023; 16(12).

PMID: 38081733 PMC: 10729263. DOI: 10.1136/bcr-2023-254702.


References
1.
Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J . Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61. PMC: 4440264. DOI: 10.1186/s13023-015-0277-y. View

2.
Yao L, Yip A, Shrader J, Mesdaghinia S, Volochayev R, Jansen A . Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology (Oxford). 2015; 55(3):441-9. PMC: 4757924. DOI: 10.1093/rheumatology/kev344. View

3.
OGrady J, Harty L, Mayer N, Critcher V, Ryan J . Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management. J Clin Med Res. 2015; 7(6):490-4. PMC: 4394925. DOI: 10.14740/jocmr2133w. View

4.
Miller T, Al-Lozi M, Lopate G, Pestronk A . Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002; 73(4):420-8. PMC: 1738058. DOI: 10.1136/jnnp.73.4.420. View

5.
Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L . Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010; 62(9):1328-34. PMC: 3107255. DOI: 10.1002/acr.20219. View